Carbamazepine-induced systemic lupus erythematosus

Area of Science:

• Neurology
• Rheumatology
• Pharmacology

Background:

• Bipolar affective disorder requires long-term maintenance treatment.
• Carbamazepine is a commonly prescribed anticonvulsant and mood stabilizer.
• Drug-induced systemic lupus erythematosus (SLE) is a recognized but uncommon phenomenon.

Observation:

• A 21-year-old woman with bipolar disorder developed SLE 18 months into carbamazepine treatment.
• The patient presented with characteristic laboratory findings of SLE.
• Central nervous system (CNS) involvement, including psychosis, is a potential manifestation of SLE.

Findings:

• Systemic lupus erythematosus (SLE) symptoms and laboratory abnormalities resolved after carbamazepine withdrawal.
• Anti-inflammatory drug treatment contributed to the remission of SLE.
• The temporal association suggests carbamazepine as a potential cause of SLE.

Implications:

• Carbamazepine should be considered a potential cause of drug-induced SLE, particularly in patients with pre-existing autoimmune predispositions.
• Clinicians should monitor for SLE symptoms in patients on long-term carbamazepine therapy.
• This case highlights the importance of considering medication side effects in the differential diagnosis of new-onset autoimmune diseases.